Attn: Office of Business Development Re: Exclusive Research Collaboration, License and Commercialization Agreement (as amended by that certain letter agreement, dated February 4, 2005, and as may be subsequently amended, the “Agreement”), effective as...Exclusive Research Collaboration, License and Commercialization Agreement • August 9th, 2006 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations
This Letter (this “Letter”) will confirm the understanding of Merck and Vertex regarding the extension of the Agreement’s Research Program Term and is intended to be legally binding on both Parties. Capitalized terms used but not otherwise defined in this Letter shall have the meanings provided in the Agreement.
Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission. LICENSE, DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION AGREEMENT by and between Vertex Pharmaceuticals...License, Development, Manufacturing and Commercialization Agreement • August 9th, 2006 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations • Massachusetts
This License, Development, Manufacturing and Commercialization Agreement (this “Agreement”) is effective as of June 30, 2006 (the “Effective Date”) and is entered into by and between Vertex Pharmaceuticals Incorporated, a Massachusetts corporation with corporate offices at 130 Waverly Street, Cambridge, MA 02139-4242, United States of America (“Vertex”) and Janssen Pharmaceutica, N.V., a Belgium corporation with corporate offices at 30, Turnhoutsesteenweg, B-2340 Beerse, Belgium (“Janssen”).
